LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Immunocore Holdings PLC ADR

Chiusa

34.1 -2.79

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.04

Massimo

34.86

Metriche Chiave

By Trading Economics

Entrata

-15M

-10M

Vendite

4.1M

98M

Margine di Profitto

-10.514

Dipendenti

493

EBITDA

-11M

-15M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+67.74% upside

Dividendi

By Dow Jones

Utili prossimi

4 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

212M

1.8B

Apertura precedente

36.89

Chiusura precedente

34.1

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Immunocore Holdings PLC ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 set 2025, 22:39 UTC

Acquisizioni, Fusioni, Takeovers

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 set 2025, 16:43 UTC

I principali Market Mover

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 set 2025, 16:42 UTC

I principali Market Mover

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 set 2025, 16:35 UTC

I principali Market Mover

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 set 2025, 23:46 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

15 set 2025, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 set 2025, 23:34 UTC

Discorsi di Mercato

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 set 2025, 22:48 UTC

Discorsi di Mercato

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 set 2025, 22:12 UTC

Acquisizioni, Fusioni, Takeovers

CSL Expects Commercial Launch in 2029

15 set 2025, 22:12 UTC

Acquisizioni, Fusioni, Takeovers

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 set 2025, 22:11 UTC

Acquisizioni, Fusioni, Takeovers

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 set 2025, 22:11 UTC

Acquisizioni, Fusioni, Takeovers

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 set 2025, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 set 2025, 21:16 UTC

Acquisizioni, Fusioni, Takeovers

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 set 2025, 21:16 UTC

Acquisizioni, Fusioni, Takeovers

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 set 2025, 21:15 UTC

Acquisizioni, Fusioni, Takeovers

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 set 2025, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 set 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 set 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

15 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

15 set 2025, 19:29 UTC

Discorsi di Mercato

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 set 2025, 19:14 UTC

Discorsi di Mercato

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 set 2025, 18:16 UTC

Discorsi di Mercato

Gold Powers to New High -- Market Talk

15 set 2025, 18:05 UTC

Discorsi di Mercato

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 set 2025, 17:50 UTC

Acquisizioni, Fusioni, Takeovers

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 set 2025, 17:10 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

15 set 2025, 17:10 UTC

Discorsi di Mercato

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 set 2025, 16:52 UTC

Discorsi di Mercato

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 set 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

15 set 2025, 16:20 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Immunocore Holdings PLC ADR Previsione

Obiettivo di Prezzo

By TipRanks

67.74% in crescita

Previsioni per 12 mesi

Media 59.11 USD  67.74%

Alto 100 USD

Basso 34 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

7

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

27.895 / 30.16Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
help-icon Live chat